HK1154574A1 - Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof - Google Patents

Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof

Info

Publication number
HK1154574A1
HK1154574A1 HK11108763.5A HK11108763A HK1154574A1 HK 1154574 A1 HK1154574 A1 HK 1154574A1 HK 11108763 A HK11108763 A HK 11108763A HK 1154574 A1 HK1154574 A1 HK 1154574A1
Authority
HK
Hong Kong
Prior art keywords
preparation methods
salts
tetrahydroimidazo
pharmaceutical use
pyrazine derivatives
Prior art date
Application number
HK11108763.5A
Other languages
English (en)
Inventor
Peng Cho Tang
Piaoyang Sun
Fanglong Yang
Jindong Liang
Guangyuan Shen
Yang Wang
Jiang Fan
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of HK1154574A1 publication Critical patent/HK1154574A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK11108763.5A 2009-03-05 2011-08-19 Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof HK1154574A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910047075A CN101824036A (zh) 2009-03-05 2009-03-05 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
PCT/CN2010/000257 WO2010099698A1 (zh) 2009-03-05 2010-03-03 四氢咪唑并[1,5-a]吡嗪衍生物的盐，其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
HK1154574A1 true HK1154574A1 (en) 2012-04-27

Family

ID=42688223

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11108763.5A HK1154574A1 (en) 2009-03-05 2011-08-19 Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof

Country Status (13)

Country Link
US (1) US8518946B2 (zh)
EP (1) EP2404921B1 (zh)
JP (1) JP5976322B2 (zh)
KR (1) KR101731602B1 (zh)
CN (2) CN101824036A (zh)
AU (1) AU2010220722B2 (zh)
CA (1) CA2753862C (zh)
HK (1) HK1154574A1 (zh)
MX (1) MX2011009190A (zh)
RU (1) RU2523543C2 (zh)
UA (1) UA106225C2 (zh)
WO (1) WO2010099698A1 (zh)
ZA (1) ZA201107284B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899048B (zh) * 2009-05-27 2013-04-17 上海恒瑞医药有限公司 (R)-7-[3-氨基-4-(2,4,5-三氟-苯基)-丁酰]-3-三氟甲基-5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸甲酯的盐
CN106892926B (zh) * 2012-10-16 2019-09-06 江苏盛迪医药有限公司 一种dpp-iv抑制剂的中间体、其制备方法和通过其制备dpp-iv抑制剂的方法
CN103664962A (zh) * 2013-12-20 2014-03-26 南京华威医药科技开发有限公司 哌嗪类衍生物
CN103910734B (zh) * 2014-03-28 2016-01-13 南京华威医药科技开发有限公司 一种具有哌嗪结构的dpp-4抑制剂
KR20240065201A (ko) 2017-07-14 2024-05-14 에프. 호프만-라 로슈 아게 이환형 케톤 화합물 및 이의 사용 방법
US20220073525A1 (en) * 2018-12-28 2022-03-10 Forma Therapeutics, Inc. Compositions for inhibiting ubiquitin specific protease 1
CN113620957B (zh) * 2020-05-08 2022-04-19 盛世泰科生物医药技术(苏州)有限公司 一种胺甲基吡嗪类化合物的制备方法
CN113773323B (zh) * 2020-06-10 2023-05-12 江苏恒瑞医药股份有限公司 3r-氨基取代丁酰胺衍生物的制备方法
CN114057751B (zh) * 2022-01-17 2022-04-12 盛世泰科生物医药技术(苏州)有限公司 一种dpp-iv抑制剂及其关键中间体的制备方法
CN115583935A (zh) * 2022-11-03 2023-01-10 浙江工业大学 一种4-(2,4,5-三氟苯基)-3-氧丁酸酯的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
FR2780974B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
CN101468988A (zh) 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
CN102159578A (zh) 2011-08-17
WO2010099698A1 (zh) 2010-09-10
KR101731602B1 (ko) 2017-04-28
UA106225C2 (ru) 2014-08-11
EP2404921A1 (en) 2012-01-11
JP2012519193A (ja) 2012-08-23
KR20110132561A (ko) 2011-12-08
CN101824036A (zh) 2010-09-08
CA2753862C (en) 2017-05-23
JP5976322B2 (ja) 2016-08-23
AU2010220722B2 (en) 2015-05-07
RU2523543C2 (ru) 2014-07-20
CN102159578B (zh) 2013-04-10
EP2404921A4 (en) 2012-08-15
MX2011009190A (es) 2011-09-26
RU2011137858A (ru) 2013-04-10
US20120065209A1 (en) 2012-03-15
AU2010220722A2 (en) 2011-11-03
AU2010220722A1 (en) 2011-10-27
US8518946B2 (en) 2013-08-27
CA2753862A1 (en) 2010-09-10
EP2404921B1 (en) 2017-11-22
ZA201107284B (en) 2012-12-27

Similar Documents

Publication Publication Date Title
HK1154574A1 (en) Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof
TN2011000247A1 (en) Organic compounds
PT2240490E (pt) Compostos orgânicos
NZ628186A (en) Compounds for treating spinal muscular atrophy
MX2010006438A (es) Derivados de tetrahidro-imidazo [1,5-a] pirazina proceso de preparacion y su uso medicinal.
IL219424A (en) Imidazo derivative [b – 1,2] pyridazine, combinations, distant preparations containing them and process for their preparation and use as pde10 inhibitors
WO2009143211A3 (en) Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
WO2012143416A3 (en) 7 - (3,5 - dimethyl - 4 - isoxazolyl) - 8 - (methyloxy) - 1h - imidazo [4,5 -c] quinoline derivatives
NZ601754A (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
NO20082757L (no) Substituerte imidazoquinoliner, imidazonaftyridiner og imidazopyridiner, sammensetninger og fremgangsmater
SI2419428T1 (sl) Imidazo (1,2-a) piridin derivati kot FGFR kinaza inhibitorji za uporabo v terapiji
WO2010012781A3 (en) New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
ZA201002009B (en) Imidazo[1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis
MX2009004700A (es) Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
NZ703111A (en) Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
ZA201100429B (en) Novel imidazo [1,2-a]pyrimidine derivatives,method for the preparation thereof,use thereof as medicaments,pharmaceutical compositions and novel use in particular as met inhibitors
EP2142543B8 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
WO2009156951A3 (en) 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
ZA201100428B (en) Imidazo [1,2-a]pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as met inhibitors
IL219371A (en) Ethylene History - (s-Triazolo / Pyrzolo) [a – 5,1] (Pyridine / Pyrimidine) and Pharmaceuticals Containing Them
HK1177207A1 (zh) 作為 激酶抑制劑用於治療心血管疾病的 -氧代- -二氫吡啶並 嘧啶衍生物
RS20080197A (en) Pyrazolo/4,3-d/pyrimidin-5-yl)derivative used as pde5 inhibitors
HK1147758A1 (zh)
WO2009034547A3 (en) New 4-substituted derivatives of pyrazolo[3,4-d pyrimidine and pyrrolo[2,3-d]pyrimidine and uses thereof
MY156428A (en) HYDRATE OF 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETHYL)-5,8-DIHYDROPYRIDO[3,4-d]PYRIMIDIN-7(6H)-YL]-4-OXOBUTYL} -5,5-DIFLUORO-PIPERIDIN-2-ONE TARTRATE

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220303